Harvard Business Review

JUNE 9, 2017

During our careers, we have worked in industry, academia, clinical medicine, and government and have managed successful academia-industry collaborations. Commonly, researchers develop a theory, then build a career gathering support for it. These scenarios are seldom contemplated in institutional management of conflicts of interest.

Conflict of Interest 10

Conflict of Interest Pharmaceuticals Policies Industry 10

Harvard Business Review

SEPTEMBER 21, 2015

Not long ago, I worked with a client who was stepping into management for the first time. Terry, a highly regarded marketing associate in a pharmaceutical firm, had just been asked to lead a marketing team. Managing Yourself Book. For most new managers, making this transition to training and coaching isn’t easy.

Management 8

Management Pharmaceuticals Learning-by-Doing Marketing 8

Chartered Management Institute

FEBRUARY 26, 2024

In a hazardous world, managers can learn from the world of scuba diving: train hard, because you’ll never get rid of risk Scroll for more Shortcut to start of content Gareth Lock, founder of The Human Diver. Want to learn more about what diving can teach managers about navigating risk? Additional reporting by David Waller.

Uncertainty 52

Uncertainty Risk Management Training Compliance 52

Harvard Business Review

OCTOBER 13, 2011

Risk management processes don't — but they should. The pharmaceutical industry also creates products with complex interactions and potentially dangerous side effects. Yet unlike in finance, where distributing risk across institutions is the goal, in drug development the focus is on isolating risk.

Banking 10

Banking Pharmaceuticals Microfinance Risk Management 10

Harvard Business Review

OCTOBER 20, 2016

Meanwhile the Institute of International Finance forecasted net capital flows for emerging markets in 2015 would be negative for the first time since 1988. Each of these shifts have consequences for how today’s multinational corporations should manage themselves. This year, for example, the U.S. And in 2014, Pfizer, the U.S.

Globalization 8

Globalization Banking Policies Politics 8

Harvard Business Review

AUGUST 2, 2011

In reality, each country needs the other to succeed in order to thrive — to finance growth, secure export markets, train talent, transfer technology, and more. For example, pharmaceutical firms license compounds to each other and co-promote products in different markets.

Apparel 15

Apparel Pharmaceuticals Finance Licensing 15

Harvard Business Review

OCTOBER 25, 2018

The superstars tend to be more involved in global flows of trade and finance, more digitally mature, and they dominate the lists of the most valued companies, the most valued brands, the most desirable places to work, and the most innovative companies. The churn rate of superstar cities is half that of superstar firms.

Industry 13

Industry Company GDP Bottom-up 13

Harvard Business Review

APRIL 19, 2016

Imagine the changes afoot in the pharmaceutical, medical device, automotive, and consumer electronics industries. This will not only challenge tax departments’ current calculations, but will also put increasing pressure on legal departments wrestling with IP asset and risk management. trillion in inventories held by U.S.

Supply Chain 8

Supply Chain Execution Analysis Technology 8

Harvard Business Review

JUNE 16, 2016

Pharmaceutical companies spend millions upon millions preparing meticulous plans for new drug launches – and yet their route-to-market strategies haven’t changed in decades, even though the reality of the market has. We must start to think differently about how business, management, and strategic intelligence works.

Planning 8

Planning Competitive Intelligence Pharmaceuticals Brand 8

Harvard Business Review

FEBRUARY 23, 2011

The first part of the conference's message, that the infrastructure of the continent is greatly wanting, was a topic of many panels, including a pair of engaging ones on technology, but it was brought home most vividly in another context, by Thierry Tanoh , a vice president at the International Finance Corp.

Conference 12

Conference Pharmaceuticals Politics Entrepreneur 12

Harvard Business Review

MARCH 14, 2017

When one of us (Vivek) and his team launched Roivant Sciences in 2014 and began developing treatments for Alzheimer’s disease — they were determined to learn from the pharma industry’s innovation issues and build a more sustainable innovation engine. Roivant’s first response was to address misaligned incentives.

Innovation 9

Innovation Company Incentives Industry 9

Harvard Business Review

MAY 26, 2014

While the managed care movement made a similar run in the early 1990s, the movement towards accountable care, bundled payments , and other population health efforts have not caused the type of backlash that managed care did ? in large part because most of these models have not meaningfully restricted patient choice.

Health Care 8

Health Care Venture Funding Entrepreneur Pharmaceuticals 8

Harvard Business Review

JUNE 29, 2015

If you ask someone who works in finance (as I had to) about PE and innovation, he or she will likely tell you that PE sponsors aren’t looking for the next big thing—they’re looking for companies that are dominant in a market, aren’t risky, and have a predictable and steady stream of cash to pay back debt.

LBO 8

LBO Innovation Sample Short-term 8

Harvard Business Review

JUNE 8, 2015

Pharmaceutical companies, buffeted by regulatory changes, new drug technologies that alter entry barriers and competition, price pressures, and an estimated 300,000 job cuts since 2000, seem to fit the popular narrative of large organizations unable to deal with disruptive forces. It’s not just products.

Health Care 8

Health Care Venture Capitalist Strategic Fit Pharmaceuticals 8

Harvard Business Review

NOVEMBER 9, 2011

That's what we found when we studied the top management teams of companies in Europe over the past three years. Part of the problem may be in the backgrounds that companies desired: 85% of COOs had experience in operations, strategy, or finance. What role does he or she play in the organization?

COO 12

COO Sample Telecommunications Automotive 12

Harvard Business Review

SEPTEMBER 5, 2016

The UK’s Department for International Development uses “results-based” aid to improve the educational outcomes of young girls in Africa and Asia. Cigna is the first insurance company to get pharmaceutical companies to agree to value pricing based on results for certain cholesterol-lowering drugs. ” Health care.

Incentives 8

Incentives Health Care Education Insurance 8

Harvard Business Review

APRIL 5, 2012

A district sales manager says: "These district sales rankings are unfair. If you know market potential by account segment, you can scale and deploy sales resources appropriately against opportunities and can develop segment-appropriate value propositions and sales processes. Coaching and performance management. Deduce the data.

Retail 9

Retail Incentives Tactics Pharmaceuticals 9

Harvard Business Review

FEBRUARY 24, 2015

Conversely, the business may be an “unpolished diamond” that was neglected by its former management for too long and whose value is just waiting to be unlocked. Does the business have a complete, balanced, and cohesive management team? Are the management team and owners prepared to abandon business as usual?

Chemicals 8

Chemicals How To Kahneman Reputation 8

Harvard Business Review

MAY 5, 2016

Within weeks there was $50 billion in business deals involving foreign companies, including the Airbus agreement (worth $25 billion) to sell 118 planes, and Italy’s state rail company’s $5 billion pact to develop the local rail network. sanctions are delaying these projects being financed. However, remaining U.S.

Tourism 8

Tourism Banking Due Diligence Hotels 8

Harvard Business Review

JANUARY 26, 2011

Companies included in the ETF include major airlines, pharmaceuticals, industrials, and technology. After our meeting at the SSE, we had lunch with Dean Xiongwen Lu and Professor Cheng-Hua Tzeng of the Fudan School of Management. Eccles is a professor of management practice at HBS. Stay tuned.

Long-term 14

Long-term Sample Report Pharmaceuticals 14

Harvard Business Review

MAY 15, 2013

Nor can we develop good approaches to analyzing, preserving and transforming cultures. If we can define what organizational culture is , it gives us a handle on how to diagnose problems and even to design and develop better cultures. finance vs. marketing) and units (e.g.

Incentives 8

Incentives Definition Pharmaceuticals System 8

Harvard Business Review

FEBRUARY 4, 2013

Levi Strauss, intriguingly, has used biomimetic techniques in developing new production techniques for jeans. Perhaps surprisingly, two leading examples come from pharmaceutical companies. Breakthrough Finance. Not only is this approach hugely impactful, but it is also "financially sustainable, and hence, scalable.".

EPS 8

EPS Innovation CEO Pharmaceuticals 8

Harvard Business Review

SEPTEMBER 4, 2015

However, CEOs often don’t have the career background and education that would equip them to personally lead the process of new product development. We found that, for pharmaceutical industry CEOs, there is a statistically significant relationship between a CEO’s specialist background and the firm’s performance.

CEO 8

CEO Innovation Pharmaceuticals Merchandising 8

Harvard Business Review

OCTOBER 24, 2014

Here are some of the challenges that I’ve observed: Product management. In addressing the billion-dollar adherence problem, Vitality (since acquired by NANTHEALTH ) considered the interests of the players in the diverse ecosystem, including pharmaceutical companies, retail pharmacies, and health care providers. Operations.

Productivity 8

Productivity Products Company Engineering 8

Harvard Business Review

NOVEMBER 20, 2015

One result is that they keep their cards close to their chests about what they are looking for (at first), while expecting you to reveal everything – your finances, pricing, ownership, human resources, production processes, quality assurance, customer service procedures, KPIs, and existing customers.

Supply Chain 8

Supply Chain Collins Golden Handcuff Pharmaceuticals 8

Harvard Business Review

SEPTEMBER 19, 2016

You have to approach these problems as a manager and do the best analysis you can, including hard-headed financial analysis. Imagine, for example, that you’re a pharmaceutical CEO deciding whether to recall a new drug. But perhaps managers have no choice. How should you make this decision?

ROI 8

ROI Long-term Conflict of Interest Pharmaceuticals 8

Harvard Business Review

JANUARY 26, 2016

We recently conducted a survey of CI managers and analysts who’ve been through our training program to see how much their findings influenced major company decisions, and why. and European corporations, from CI-trained analysts in marketing, business development, strategy, R&D, finance, and other fields.

Competitive Intelligence 8

Competitive Intelligence Company CAPEX Analysis 8

Harvard Business Review

JUNE 20, 2017

While consumer spending has proven resilient, with same-store retail sales rising 6% YOY in April , most multinational corporations are developing contingency plans to mitigate risks to their businesses and reassessing the country’s role in their global market portfolio and supply chains. Renegotiating NAFTA.

Supply Chain 9

Supply Chain Depreciation Uncertainty Marketing 9

Harvard Business Review

AUGUST 23, 2016

Republicans generally favor developing a pipeline of diverse candidates through director advocacy and mentorship, while Democrats are more likely to favor requiring that every director slate include diverse candidates, or that boards implement targets for diverse membership. chemicals, metals & mining, paper & forest products).

Politics 8

Politics Committee Telecommunications Diversity 8